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Abstract: Ruthenium compounds have shown to be promising 
alternatives to platinum(II) drugs. However, their clinical success 
depends on achieving mechanisms of action that overcome Pt-
resistance mechanisms. Electron-deficient organoruthenium 
complexes are an understudied class of compounds which exhibit 
unusual reactivity in solution and may offer novel anticancer 
mechanisms of action. Here, we evaluate the in vitro and in vivo 
anticancer properties of the electron-deficient organoruthenium 
complex [(p-cymene)Ru(maleonitriledithiolate)]. This compound is 
found to be highly cytotoxic: 5 to 60 times more potent than cisplatin 
towards ovarian (A2780 and A2780cisR), colon (HCT116 p53+/+ and 
HCT116 p53-/-), and non-small lung H460 cancer cell lines. It shows 
no cross-resistance and is equally cytotoxic to both A2780 and 
A2780cisR cell lines. Furthermore, unlike cisplatin, the remarkable in 
vitro antiproliferative activity of this compound appears to be p53-
independent. In vivo evaluation in the hollow fibre assay across a 
panel of cancer cell types and subcutaneous H460 non-small cell lung 
cancer xenograft model hints at activity of the complex. Although the 
impressive in vitro data are not fully corroborated by the in vivo follow-
up, this work is the first preclinical study of electron-deficient half-
sandwich complexes and highlights their promises as anticancer drug 
candidates. 
Introduction 
There is an urgent need to find molecules with different anticancer 
mechanisms of action (MoA) than platinum(II) drugs, particularly 
for patients who relapse after having been initially treated with a 
platinum-containing chemotherapy regimen (ca. 50% of all 
anticancer chemotherapy treatments[1]). In this context, 
ruthenium-based drugs are promising[2] with several complexes 
exhibiting their anticancer properties via MoA different than 
nuclear DNA binding. For example, half-sandwich ruthenium 
complexes have shown great potential as catalytic metallodrug 
candidates,[3] some inert polypyridyl Ru(II) complexes target 
mitochondria and induce apoptosis[4] while other inert octahedral 
Ru(II) complexes can act as highly potent and selective inhibitors 
of kinases.[5]  
A class of under-explored ruthenium compounds is the family of 
electron-deficient half-sandwich complexes. Electron-deficient 
organometallics are involved in a number of catalytic processes 
as generally unstable intermediates, thus rendering their use as 
metallodrug candidates difficult.[6] Nonetheless, the groups of 
Suzuki, Koelle, Tilley among others reported some stable 
coordinatively unsaturated 16-electron (16-e) organometallics.[7] 
We have recently developed a strong interest in elucidating the 
chemistry of 16-e dithiolate-half-sandwich complexes of precious 
metals (Ru, Os, Rh, Ir). Their unusual reactivity in solution (e.g. 
thermochromism,[8] lack of reactivity with σ-donor ligands and/or 
σ-donor/π-acceptor ligands,[9] carbon monoxide 
capture/release,[10] behavior under irradiation[11]) makes them 
fascinating molecules to study. We also investigated their 
anticancer[12] and anti-inflammatory properties,[13] as well as their 
potential for boron neutron capture therapy.[14] 
In our efforts to confirm/infirm the anticancer potential of such 
electron-deficient organometallics, the antiproliferative activity of 
the 16-e complex [(p-cymene)Ru(maleonitriledithiolate)] (1) 
towards ovarian (A2780 and A2780cisR), colon (HCT116 p53+/+ 
and HCT116 p53-/-), and lung (H460) cancer cells is reported 
herein. The stability in solution and reactivity with potential 
(bio)ligands is investigated, while the MoA of this metal complex 
is studied via gene expression studies, cell cycle analysis, and N-
acetylcysteine (NAC) co-incubation assay. Finally, the complex is 
progressed in vivo to assess toxicity and efficacy. The maximum 
tolerated dose is determined, along with the effects of 1 on human 
tumor cell lines grown in hollow fibers implanted subcutaneously 
or intraperitoneally in mice (hollow fiber assay; HFA), and in a 
human H460 non-small cell lung cancer (NSCLC) subcutaneous 
tumor xenograft model. 
Results and Discussion 
Stability studies 
 
Complex 1 was synthesized according to a previously reported 
method.[15] Its stability in the presence of different solvents or 
reactants was first evaluated. Owing to poor water-solubility at 
millimolar concentration, complex 1 was dissolved in pure 
deuterated dimethylsulfoxide (DMSO-d6) (1.1 mM concentration; 
Figure 1(A)) and spectra at t = 0 h, 24 h, 48 h were recorded. The 
complex is stable under these conditions, although a slight loss of 
para-cymene can be observed (free p-cym signals at ca. 7.2 ppm) 
after 24 hours. Nonetheless, complex 1 does not significantly 
decompose in pure DMSO at millimolar concentration and the 
complex is expected to be stable at micromolar concentration in 
the drug-media solutions which are added to cells (the final DMSO 
concentrations being less than 0.5% (v/v) in all cases).  
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The reactivity of complex 1 was then evaluated in the presence of 
1 mol. equiv. glutathione (GSH) by 1H NMR spectroscopy (298K, 
CD3CN:D2O, 1:1 v/v; 1.1 mM). Glutathione is involved in cisplatin 
resistance mechanisms. Indeed, the redox-regulating capacity of 
GSH is involved in detoxifying cisplatin while GSH also regulates 
the intracellular copper pool that affects cisplatin uptake.[16] 
Furthermore, reactivity between complex 1 and GSH could lead 
to facile excretion of the 18-e GSH-adduct from the cells. As can 
be seen in Figure 1(B), no reaction occurs between complex 1 
and 1 mol. equiv. of GSH, which indicates that the electron-
deficient complex does not accept electrons from the electron-
donor ligand.  
 
Nucleobase binding studies were then carried out with 2 mol. 
equiv. of 9-ethylguanine or 9-methyladenine using 1H NMR 
spectroscopy (298K, CD3CN:D2O, 1:1 v/v; 1.1 mM). The spectra 
show that complex 1 does not react with 9-ethylguanine (Figure 
1(C)), nor with of 9-methyladenine (Figure 1(D)). The remarkable 
inertness of electron-deficient complex 1 is further demonstrated 
by the absence of reactivity with 4-dimethylaminopyridine, a 
strong σ-donor ligand (Figure S1). However, in the presence of 
the σ-donor/π-acceptor triphenylphosphine ligand, the 18-e 
adduct [(p-cymene)Ru(maleonitriledithiolate)PPh3] can be 




















Figure 1. Stability studies for complex 1. (A) 1H NMR spectra of complex 1 in 
DMSO-d6 over a period of 0 – 48 h (298K, 1.1 mM); (B) 1H NMR spectra of 
complex 1 + 1 mol. equiv. GSH in a mixture CD3CN:D2O, 1:1 v/v (298K, 1.1 mM) 
over a period of 0 – 48 h; (C) 1H NMR spectra of complex 1 + 2 mol. equiv. 9-
ethylguanine in a mixture CD3CN:D2O, 1:1 v/v (298K, [1] = 1.1 mM) over a 
period of 0 – 48 h; (D) 1H NMR spectra of complex 1 + 2 mol. equiv. 9-
methyladenine in a mixture CD3CN:D2O, 1:1 v/v (298K, [1] = 1.1 mM) over a 
period of 0 – 48 h. 
In vitro antiproliferative activity 
 
Chemosensitivity studies were undertaken using a 24-hour MTT 
assay, with a 72-hour recovery period. The IC50 values (which 
correspond to inhibitions of cancer-cell growth at the 50% levels) 
were determined against HCT116 p53+/+ (human colorectal 
carcinoma, p53-wt), HCT116 p53-/- (human colorectal carcinoma, 
p53-null), A2780 (ovarian adenocarcinoma), A2780cisR 
(cisplatin-resistant variant of A2780), and H460 (NSCLC) 
exposed to compound 1 or cisplatin (Table 1, Figure S3). 
 
Complex 1 is highly active towards all cell lines (5 to 70  more 
active than cisplatin), with IC50 values in the nanomolar range 
against ovarian and lung cancer cells, and in the low micromolar 
range against colon cancer cells. This metal compound ranks 
among the most active half-sandwich complexes ever reported, 
and compares well with the highly potent thiolato-bridged arene 
ruthenium complexes reported by Süss-Fink, Therrien and co-
workers in 2012.[17] 
 
Table 1. IC50 values / M ± SD (triplicates of triplicates) for cisplatin and 
compound 1 against HCT116 p53+/+, HCT116 p53-/-, A2780, A2780cisR, and 
H460 cell lines. 
Comple
x 
















cisplatin 51±17 67±22 8±1 18±1 4.0±0.
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Furthermore, compound 1 is highly cytotoxic against the difficult-
to-treat colorectal HCT116 p53-/- cells. A current limitation in the 
treatment of colorectal cancer is the reduced cytotoxicity of 
clinically used chemotherapeutics towards cancer cells which lack 
the tumor suppressor p53.[18] Identifying molecules that are active 
towards both p53 wild‐type and p53‐null isogenic cancer cell 
clones of the human cancer cell line HCT116 is therefore of great 
interest.[19] 
 
Another important result is the submicromolar activity of 
compound 1 against A2780cisR. Ovarian cancers are commonly 
treated with platinum-containing regimens,[20] and acquired and 
intrinsic resistance mechanisms limit the efficacy of Pt-
chemotherapy. The ability of complex 1 to circumvent Pt 
resistance mechanisms is therefore of interest. 
 
Gene expression studies 
 
To gain an insight into the possible anticancer MoA of complex 1, 
gene expression studies were then carried out in HCT116 p53+/+ 
and HCT116 p53-/- cells on a panel of genes involved in 
apoptosis and DNA damage repair response (Figure 2 and Table 
S1 for the names, primers sequences and roles of the genes used 
in this study). Complex 1 induces significant upregulation of some 
key genes associated to apoptosis, including BAX and CDKN1A 
genes (600% and 900% increase, respectively). Furthermore, 
complex 1 only induces moderate DNA damage response: 
ALKBH2 is upregulated, a gene involved in the protection against 
methylating agents which induces repair of DNA lesions.[21] 
Moreover, the expression level of PARP1 is moderately increased, 






which indicates a repair of modified bases,[22] as does the 
upregulation of BRCA1 which facilitates homologous 
recombination to maintain genomic stability.[23] These results 
suggest that complex 1 might have a different MoA than cisplatin 
(as the chemosensitivity studies on A2780cisR already 
suggested), which has been shown to significantly upregulate 
genes involved in DNA damage response and repair (e.g., PARP1, 
BRCA1, ALKBH3, RAD51; which is consistent with the DNA 
alkylating MoA of cisplatin).[24] 
 
 
Figure 2. Percentage of increase/decrease of genes expressed in HCT116 
p53+/+ and HCT116 p53-/- cells treated with complex 1. 
Cell cycle analysis 
 
Apoptosis induced by 1 in HCT116 p53+/+ and A2780 cells was 
confirmed by flow cytometry and cell cycle analysis. Flow 
cytometry allows a precise analysis of the impact of various 
functional modulators on the cell cycle,[25] and apoptosis can be 
detected from the loss of DNA from permeabilized cells. The 
permeabilization leads to fragmented DNA multimers leaking out 
of the cells and therefore results in a population of cells with a 
reduced DNA content. The DNA profile representing cells in G1, 
S-phase and G2M will be obtained with apoptotic cells being 
represented by a subG population. Figure 3 shows that compound 
1 induces a significant increase of subG populations (43% in 
HCT116 p53+/+ and 68% in A2780), which thus confirms the 




























Figure 3. Cell cycle analysis of HCT116 p53+/+ (A) and A2780 (B) cells treated 
with cisplatin or compound 1. 
Cell viability with N-acetylcysteine 
 
The DNA damage response suggested by the gene expression 
study is not in accordance with the inertness of compound 1 
towards biomolecules, and nucleobases in particular. We 
therefore hypothesized that complex 1 could lead to apoptosis via 
generation of reactive oxygen species (ROS). To test this 
hypothesis, HCT116 p53+/+ and HCT116 p53-/- cells were co-
incubated with a large excess of N-acetylcysteine (NAC; 5 and 10 
mM) 30 minutes prior to the treatment with complex 1 (at the IC50 
values). NAC is a known reductant which is used to protect the 
cells from ROS and oxidative stress. Pre-treatment with NAC at 
high concentrations inhibits the cytotoxic activity of complex 1 for 
both cell lines (Figure 4), which suggests that NAC protects the 
cells from the effect of complex 1 (indeed, 1 and NAC do not react 
together, which therefore rules out a deactivation of the metal 













Figure 4. Cell viability of HCT116 p53+/+ and HCT116 p53-/- cells at the IC50 
concentration of complex 1 in the presence of a large excess of NAC. 
ROS Analysis 
To confirm the hypothesis of induction of oxidative stress by 
complex 1, the intracellular production of ROS was investigated 
using the fluorescent DCFH2-DA assay and flow cytometry with 
A2780 cells either left untreated, or exposed to 1 (IC50 
concentration), or to H2O2 as a positive control (200 μM), or to  
NAC as a negative control (5 mM). After 5 h drug incubation, it 






can be observed that ROS levels in treated cells are significantly 
higher than in untreated cells (Figure 5). Furthermore, the ROS 
levels of treated cells are comparable to those of cells treated with 







Figure 5. Induction of ROS in A2780 ovarian cancer cells using complex 1 (IC50 
concentration) and 5 h drug exposure. Controls with NAC (ROS inhibitor; 5mM) 
and H2O2 (200 μM) were also performed under the same conditions. 
In vivo toxicity studies 
 
Since compound 1 showed great promise in vitro, preclinical 
studies were progressed in vivo. Initially the maximum tolerated 
dose (MTD) of complex 1 was established as 7.5 mgkg-1 when 
administered intraperitoneally (i.p.) daily for 4 days and monitored 
for a further 2 weeks. This is more than 3 times the MTD of 
cisplatin.  
 
Following the establishment of the MTD for compound 1, a 
preliminary in vivo efficacy screening was carried out using the in 
vivo hollow fibre assay (HFA). This assay was developed at the 
NCI, and bridges the gap between cell-based assays and in vivo 
xenograft studies in immunodeficient mice.[26] This intermediate 
assay, in a cell line panel, helps predict the activity a compound 
would have in a subsequent xenograft system. The method is 
based on propagating human cancer cells in inert hollow fibres 
with pores small enough to retain cancer cells but large enough 
to permit entry of potential chemotherapeutic drugs. Fibres which 
contain cancer cells are injected in the peritoneum (i.p.) or under 
the skin (s.c.). The host mice are then treated with the drug 
candidates through i.p. injection. The fibres are then retrieved for 
analysis of viable cell mass using a modified MTT assay. This 
assay has significant 3Rs benefits in terms of reducing the 
number of animals required, as well the refinement of a short 
assay time. The HFA was run with 5 cell lines: DLD-1 (colorectal 
adenocarcinoma cell line), H460, and MDA-MB-231 (breast 
cancer cell line), plus A2780 and A2780cisR in a second cohort. 
In the HFA the effects of a drug candidate on cell growth is 
determined in cells grown in hollow fibres implanted 
subcutaneously or intraperitoneally in mice on day 0. Using a 
standardised US National Cancer Institute protocol,[27] complex 1 
(7.5mg/kg/dose) and cisplatin (2mg/kg/dose) were administered 
i.p. daily on days 3 to 6, with fibres retrieved for analysis on day 
7. Significant reduction in growth (p<0.1) was seen in most cell 
lines for complex 1 for the i.p. implanted fibres, with less of an 
effect seen for the s.c. fibres. The fact that, for most cell lines, the 
compound lost activity when injected away from the fibres 
suggests issues with bioavailability of complex 1 and this will need 
to be investigated in a future study (Figure 6). However, in the 
cases of H460 and A2780cisR cells, such loss of activity between 
i.p. and s.c. implanted fibres was not observed, and we therefore 
chose to evaluate the efficacy of compound 1 in an H460 
subcutaneous tumour xenograft model as it is more reliable in 

















Figure 6. Activity of complex 1 against a panel of cancer cells in vivo in the HFA. 
Each cell line was implanted either intraperitoneally (i.p.) or subcutaneously 
(s.c.) in mice and treated with 1 (7.5 mg/kg) administered i.p. on days 3, 4, 5 
and 6 after implantation. 
The results from the more comprehensive evaluation of efficacy 
carried out in an H460 subcutaneous tumour xenograft model are 
shown in Figure 7. Complex 1 showed negligible signs of toxicity 
over the duration of the study, whereas some weight loss was 
observed with cisplatin (Figure S5). A reduction in tumour growth 
compared to the untreated and cisplatin control groups was 
evident over the first four days of treatment, with the growth delay 
being statistically significant on day 3. However the effect did not 
continue when further treatments were administered from day 7, 









































Figure 7. Xenograft study of the therapy of H460 tumours with complex 1 and 
cisplatin (mean relative tumour volume ± SEM against time). 
Conclusions 
In conclusion, the data presented herein demonstrates that [(p-
cymene)Ru(maleonitriledithiolate)], although electron-deficient at 
the metal center, is a chemically inert metal complex which does 
not interact with biomolecules acting as poisons for a number of 
organometallics. As a result, this complex shows remarkable 
antiproliferative and apoptotic properties in vitro, while being 
equally cytotoxic to cisplatin-sensitive and -resistant cell lines. 
Furthermore, the mechanism of action of this compound appears 
to be p53-independent. Whilst in vivo results were not as 
impressive as the in vitro data due to poor bioavailability, the 
slightly significant activity seen for the i.p.-implanted hollow fibers, 
and initial growth delay seen in the H460 xenograft model give 
encouragement for this class of molecules if suitable structural 
modifications can be carried out to improve bioavailability. 
Complex 1 is therefore a promising lead compound with a 
different MoA than cisplatin, being p53-independent, and resisting 
deactivation by sulfur- and nitrogen-containing biomolecules. We 
believe that these results highlight the potential of electron-
deficient organometallics as anticancer drug candidates. 
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